The browser you are using is not supported by this website. All versions of Internet Explorer are no longer supported, either by us or Microsoft (read more here: https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).

Please use a modern browser to fully experience our website, such as the newest versions of Edge, Chrome, Firefox or Safari etc.

Default user image.

Gustav Smith

Associate professor

Default user image.

A pharmacodynamic comparison of 5 anti-platelet protocols in patients with ST-elevation myocardial infarction undergoing primary PCI.

Author

  • Sasha Koul
  • Pontus Andell
  • Andreas Martinsson
  • Gustav Smith
  • Fredrik Scherstén
  • Jan Harnek
  • Matthias Götberg
  • Eva Norström
  • Sven Björnsson
  • David Erlinge

Summary, in English

Despite advances in anti-platelet treatments, there still exists an early increase in both ischemic as well as bleeding events following primary PCI in patients with ST-elevation myocardial infarction (STEMI). Platelet inhibition data of different anti-platelet treatments in the acute phase of a myocardial infarction might offer some insight into these problems. The aim of this study was to evaluate the pharmacodynamic profile of 5 different anti-platelet treatments in the acute phase of STEMI in patients undergoing primary PCI.

Department/s

  • Cardiology
  • Division of Hematology and Transfusion Medicine
  • Clinical Chemistry, Malmö
  • EXODIAB: Excellence of Diabetes Research in Sweden
  • EpiHealth: Epidemiology for Health

Publishing year

2014

Language

English

Publication/Series

BMC Cardiovascular Disorders

Volume

14

Document type

Journal article

Publisher

BioMed Central (BMC)

Topic

  • Cardiac and Cardiovascular Systems

Status

Published

Research group

  • Clinical Chemistry, Malmö

ISBN/ISSN/Other

  • ISSN: 1471-2261